Innate Pharma SA Files 20-F Report for Fiscal Year Ended December 31, 2023

Ticker: IPHYF · Form: 20-F · Filed: Apr 4, 2024 · CIK: 1598599

Innate Pharma SA 20-F Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type20-F
Filed DateApr 4, 2024
Risk Levellow
Pages15
Reading Time17 min
Key Dollar Amounts$
Sentimentneutral

Sentiment: neutral

Topics: 20-F, Innate Pharma, Annual Report, SEC Filing, Biotechnology

TL;DR

<b>Innate Pharma SA has submitted its 20-F annual report detailing its 2023 fiscal year performance and corporate information.</b>

AI Summary

Innate Pharma SA (IPHYF) filed a Foreign Annual Report (20-F) with the SEC on April 4, 2024. Innate Pharma SA filed its annual 20-F report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company is incorporated in I0 and its fiscal year ends on December 31. Innate Pharma SA's business address is 117 Avenue de Luminy, BP 30191, Marseille, I0, 13009. The company previously operated under the name Innate Pharma, SA until January 29, 2014.

Why It Matters

For investors and stakeholders tracking Innate Pharma SA, this filing contains several important signals. This filing provides a comprehensive overview of Innate Pharma SA's financial and operational status for the 2023 fiscal year, crucial for investors and stakeholders to assess the company's performance and outlook. As a foreign private issuer, the 20-F filing is a key document for US investors to understand the company's governance, financial statements, and risk factors under SEC regulations.

Risk Assessment

Risk Level: low — Innate Pharma SA shows low risk based on this filing. The filing is a routine annual report and does not contain immediate material news, indicating a stable, ongoing operational status.

Analyst Insight

Review the full 20-F filing for detailed financial statements, management discussion, and risk factors to understand Innate Pharma SA's strategic direction and potential investment implications.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Conformed period of report)
  • 2024-04-04 — Filing Date (Filed as of date)
  • 2023 — Fiscal Year (FY 2023)

Key Players & Entities

  • Innate Pharma SA (company) — Filer name
  • 20231231 (date) — Conformed period of report
  • 20240404 (date) — Filed as of date
  • 117 Avenue de Luminy (address) — Business address street 1
  • Marseille (city) — Business address city
  • 13009 (zip_code) — Business address zip
  • Innate Pharma, SA (company) — Former company name
  • 20140129 (date) — Date of name change

FAQ

When did Innate Pharma SA file this 20-F?

Innate Pharma SA filed this Foreign Annual Report (20-F) with the SEC on April 4, 2024.

What is a 20-F filing?

A 20-F is a annual report for foreign private issuers, equivalent to a 10-K but following international reporting standards. This particular 20-F was filed by Innate Pharma SA (IPHYF).

Where can I read the original 20-F filing from Innate Pharma SA?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Innate Pharma SA.

What are the key takeaways from Innate Pharma SA's 20-F?

Innate Pharma SA filed this 20-F on April 4, 2024. Key takeaways: Innate Pharma SA filed its annual 20-F report for the fiscal year ending December 31, 2023.. The filing covers the period from January 1, 2023, to December 31, 2023.. The company is incorporated in I0 and its fiscal year ends on December 31..

Is Innate Pharma SA a risky investment based on this filing?

Based on this 20-F, Innate Pharma SA presents a relatively low-risk profile. The filing is a routine annual report and does not contain immediate material news, indicating a stable, ongoing operational status.

What should investors do after reading Innate Pharma SA's 20-F?

Review the full 20-F filing for detailed financial statements, management discussion, and risk factors to understand Innate Pharma SA's strategic direction and potential investment implications. The overall sentiment from this filing is neutral.

How does Innate Pharma SA compare to its industry peers?

Innate Pharma SA operates in the biotechnology sector, focusing on the development of innovative therapies.

Are there regulatory concerns for Innate Pharma SA?

As a foreign private issuer, Innate Pharma SA is subject to SEC regulations, including the requirement to file annual reports like the 20-F.

Industry Context

Innate Pharma SA operates in the biotechnology sector, focusing on the development of innovative therapies.

Regulatory Implications

As a foreign private issuer, Innate Pharma SA is subject to SEC regulations, including the requirement to file annual reports like the 20-F.

What Investors Should Do

  1. Analyze the financial statements within the 20-F for revenue, expenses, and cash flow.
  2. Review the Management's Discussion and Analysis section for insights into business strategy and outlook.
  3. Examine the risk factors section for potential challenges and uncertainties facing the company.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the 20-F filing.
  • 2024-04-04: Filing Date — Date the 20-F report was officially submitted to the SEC.

Glossary

20-F
An annual report required by the U.S. Securities and Exchange Commission (SEC) for foreign private issuers. (Provides comprehensive financial and operational information for investors.)

Year-Over-Year Comparison

This filing is the annual 20-F report for the fiscal year 2023, providing updated information compared to previous filings.

Filing Stats: 4,369 words · 17 min read · ~15 pages · Grade level 13.2 · Accepted 2024-04-04 08:03:29

Key Financial Figures

  • $ — ll references in this Annual Report to "$," "US$," "U.S.$," "U.S. dollars," "doll

Filing Documents

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No TABLE OF CONTENTS INTRODUCTION 6 PART I 10

Identity of Directors, Senior Management and Advisers

Item 1. Identity of Directors, Senior Management and Advisers. 10

Offer Statistics and Expected Timetable

Item 2. Offer Statistics and Expected Timetable. 10

Key Information

Item 3. Key Information. 10 A. Reserved 10 B. Capitalization and Indebtedness 10 C. Reasons for the Offer and Use of Proceeds 10 D. Risk Factors 10

Information on the Company

Item 4. Information on the Company. 74 A. History and Development of the Company 74 B. Business Overview 75 C. Organizational Structure. 132 D. Property, Plants and Equipment. 132

Unresolved Staff Comments

Item 4A. Unresolved Staff Comments. 132

Operating and Financial Review and Prospects

Item 5. Operating and Financial Review and Prospects. 132 A. Operating Results 139 B. Liquidity and Capital Resources 160 C. Research and Development 168 D. Trend Information 168 E . Critical Accounting Estimates . 168

Directors, Senior Management and Employee

Item 6. Directors, Senior Management and Employee. 168 A. Directors and Senior Management. 169 B. Compensation. 175 C. Board Practices 187 D. Employees 193 E. Share Ownership. 194 F. Disclosure of any action to recover erroneously awarded compensation 194

Major Shareholders and Related Party Transactions

Item 7. Major Shareholders and Related Party Transactions 195 A. Major Shareholders 195 B. Related Party Transactions. 197 C. Interests of Experts and Counsel. 200

Financial Information

Item 8. Financial Information 200 A. Consolidated Statements and Other Financial Information. 200 B. Significant Changes. 201

The Offer and Listing

Item 9. The Offer and Listing. 201 A. Offer and Listing Details. 201 3 B. Plan of Distribution. 201 C. Markets. 201 D. Selling Shareholders. 201 E. Dilution. 201 F. Expenses of the Issue. 201

Additional Information

Item 10. Additional Information. 201 A. Share Capital. 201 B. Memorandum and Articles of Association. 201 C. Material Contracts. 206 D. Exchange Controls. 215 E. Taxation. 215 F. Dividends and Paying Agents. 226 G. Statement by Experts. 226 H. Documents on Display. 226 I. Subsidiary Information. 227 J. Annual Report to Security Holders 227

Quantitative and Qualitative Disclosures About Market Risk

Item 11. Quantitative and Qualitative Disclosures About Market Risk. 227

Description of Securities Other than Equity Securities

Item 12. Description of Securities Other than Equity Securities. 229 A. Debt Securities. 229 B. Warrants and Rights. 229 C. Other Securities. 229 D. American Depositary Shares. 229 PART II 232

Defaults, Dividend Arrearages and Delinquencies

Item 13. Defaults, Dividend Arrearages and Delinquencies. 232

Material Modifications to the Rights of Security Holders and Use of Proceeds

Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds. 232

Controls and Procedures

Item 15. Controls and Procedures. 232

Reserved

Item 16. Reserved. 234

Audit Committees Financial Expert

Item 16A. Audit Committees Financial Expert. 234

Code of Business Conduct and Ethics

Item 16B. Code of Business Conduct and Ethics. 234

Principal Accountant Fees and Services

Item 16C. Principal Accountant Fees and Services. 234

Exemptions from the Listing Standards for Audit Committees

Item 16D. Exemptions from the Listing Standards for Audit Committees. 235

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers. 235

Change in Registrant's Certifying Accountant

Item 16F. Change in Registrant's Certifying Accountant. 235

Corporate Governance

Item 16G. Corporate Governance. 235

Mine Safety Disclosure

Item 16H. Mine Safety Disclosure. 237

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 237

Insider Trading Policies

Item 16J. Insider Trading Policies 237

Cybersecurity

Item 16K. Cybersecurity 237 PART III 238 4

Financial Statements

Item 17. Financial Statements. 238

Financial Statements

Item 18. Financial Statements. 238

Exhibits

Item 19. Exhibits. 238 5 INTRODUCTION Unless otherwise indicated in this annual report (this "Annual Report"), "Innate Pharma," "Innate," "the company," "the Company," "we," "us" and "our" refer to Innate Pharma S.A. and its consolidated subsidiaries. "Innate Pharma," the Innate Pharma logo, ANKET and other trademarks or service marks of Innate Pharma S.A. appearing in this Annual Report are the property of Innate Pharma S.A. or its subsidiaries. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report are listed without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All other trademarks, trade names and service marks appearing in this Annual Report are the property of their respective owners. The Company does not intend to use or display other companies' trademarks and trade names to imply any relationship with, or endorsement or sponsorship of Innate by, any other companies. The audited consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). The consolidated financial statements are presented in euros, and unless otherwise specified, all monetary amounts are in euros. All references in this Annual Report to "$," "US$," "U.S.$," "U.S. dollars," "dollars" and "USD" mean U.S. dollars and all references to "" and "euros" mean euros, unless otherwise noted. Throughout this Annual Report, references to ADSs mean American Depositary Shares or ordinary shares represented by such ADSs, as the case may be. 6 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as a

Identity of Directors, Senior Management and Advisers

Item 1. Identity of Directors, Senior Management and Advisers. Not applicable.

Offer Statistics and Expected Timetable

Item 2. Offer Statistics and Expected Timetable. Not applicable.

Key Information

Item 3. Key Information. A. [Reserved] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. 10 D. Risk Factors The Company's business faces significant risks. You should carefully consider all of the information set forth in this Annual Report and in the other filings with the SEC, including the following risk factors which Innate faces and which are faced by its industry. The Company's business, financial condition or results of operations could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Innate's results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors, including the risks described below and elsewhere in this Annual Report and its other SEC filings. See "Special Note Regarding Forward-Looking Statements" above. Risks Related to the Development of the Product Candidates Biopharmaceutical development involves a high degree of uncertainty and most of the product candidates are in early stages of development, which makes it difficult to evaluate the current business and future prospects and may increase the risk of your investment. Innate Pharma is a global, clinical stage oncology-focused biotech company developing a portfolio of product candidates, some of which Innate is co-developing, in the early stages of clinical development and preclinical programs. A key element of Innate's strategy is to mature and expand its portfolio of proprietary and partnered product candidates to address unmet medical needs in immuno-oncology. Although Innate's research and development efforts to date have resulted in a pipeline of product candidates, all of its product candidates require additional development, regulatory review and approvals, substantial investment, access to sufficient commercial manufacturing capacity and significant marke

View Full Filing

View this 20-F filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.